Further, our prognostic index predicts individualised spatially specific changes in tau accumulation in CN individuals, enabling fine stratification and staging at asymptomatic stages of AD (i.e., before clinical symptom occurrence). The gene discussed is MAPT; the disease is Alzheimer disease.